Trump’s Pharma Pricing Deal Expands as Healthcare Stocks Keep Climbing
Trump pharma pricing deal healthcare stocks rally. Photo by BeInCrypto Healthcare stocks wrapped up their best quarter yet,…
Pancreatic cancer drug approval: FDA OKs Revolution Medicines’ daily pills
WASHINGTON (AP) — The Food and Drug Administration on Wednesday approved a groundbreaking new drug for advanced pancreatic…
Revolution Medicines’ New Drug Application for Daraxonrasib Accepted for Review by U.S. FDA for Previously Treated Metastatic Pancreatic Cancer
Revolution Medicines, Inc. REDWOOD CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a…
Better Growth Buy: Axsome vs Revolution Medicines
Axsome Therapeutics (NASDAQ: AXSM) and Revolution Medicines (NASDAQ: RVMD) have offered investors significant growth so far this year.…
European Medicines Agency Expedites Assessment of Revolution Medicines’ Daraxonrasib Under Phased Review Process
Revolution Medicines, Inc. REDWOOD CITY, Calif., July 07, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a…
Why Revolution Medicines (RVMD) Is Up 6.2% After Early Zoldonrasib Pancreatic Cancer Data And What’s Next
In late June and early July 2026, Revolution Medicines reported Phase 1/2 data showing that its RAS G12D…
Revolution Medicines Presents Phase 1/2 Clinical Data for Zoldonrasib Combination Regimens in Patients with RAS G12D Metastatic Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026
Revolution Medicines, Inc. REDWOOD CITY, Calif., July 02, 2026 (GLOBE NEWSWIRE) — Revolution Medicines, Inc. (Nasdaq: RVMD), a…
How FDA Expanded Access for Daraxonrasib and Phase 3 Survival Data At Revolution Medicines (RVMD) Has Changed Its Investment Story
Revolution Medicines recently secured FDA clearance for an expanded access program for its investigational pancreatic cancer drug daraxonrasib,…
Is It Too Late To Consider Revolution Medicines (RVMD) After Its Recent 50% Weekly Surge?
If you are wondering whether Revolution Medicines is still worth considering after its recent run, this article will…